Teachers Retirement System of The State of Kentucky Buys 52,000 Shares of Medtronic PLC $MDT

Teachers Retirement System of The State of Kentucky boosted its stake in shares of Medtronic PLC (NYSE:MDT) by 9.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 596,959 shares of the medical technology company’s stock after buying an additional 52,000 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Medtronic were worth $57,345,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Medtronic by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock valued at $12,388,027,000 after acquiring an additional 1,888,381 shares during the last quarter. State Street Corp lifted its holdings in shares of Medtronic by 1.0% in the 3rd quarter. State Street Corp now owns 60,460,537 shares of the medical technology company’s stock worth $5,800,550,000 after acquiring an additional 625,992 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Medtronic by 0.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock worth $2,044,637,000 after purchasing an additional 192,410 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Medtronic by 0.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after purchasing an additional 98,220 shares during the period. Finally, Raymond James Financial Inc. grew its holdings in Medtronic by 3.0% during the 3rd quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company’s stock valued at $1,067,055,000 after purchasing an additional 327,899 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Jefferies Financial Group reissued a “hold” rating and issued a $95.00 price objective on shares of Medtronic in a research note on Thursday. Evercore set a $106.00 target price on Medtronic and gave the company an “outperform” rating in a research note on Thursday, April 9th. Sanford C. Bernstein increased their price target on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Needham & Company LLC reissued a “buy” rating and set a $120.00 price target on shares of Medtronic in a research note on Thursday, March 26th. Finally, Piper Sandler dropped their price objective on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a report on Wednesday, April 1st. Fifteen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.

Medtronic Trading Down 0.5%

Shares of MDT opened at $83.36 on Friday. The firm has a market capitalization of $107.03 billion, a price-to-earnings ratio of 23.22, a PEG ratio of 2.18 and a beta of 0.75. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a 1-year low of $79.93 and a 1-year high of $106.33. The company has a 50-day moving average of $89.78 and a 200 day moving average of $95.23.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts expect that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.4%. Medtronic’s dividend payout ratio is 79.11%.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.26% of the stock is currently owned by company insiders.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Completed CathWorks acquisition and $100M investment in Pulnovo expand Medtronic’s AI and cardiovascular diagnostics/therapy footprint — these moves boost long‑term addressable market and product pipeline relevance. Medtronic Expands AI Heart Care As Investors Weigh Valuation And Momentum
• Positive Sentiment: Market reports highlight sizable growth opportunities (automated insulin delivery, catheters, long‑term/home healthcare) where Medtronic is a listed participant — supports longer‑term revenue runway assumptions. 2026 HoustonCISO ORBIE Awards Recognize Top Security Executives
• Neutral Sentiment: Analysts (Jefferies) reiterate a Hold with a $95 target, reflecting valuation compression and a slower growth outlook; not a catalyst for a large rerating but keeps expectations muted. Medtronic: Portfolio Streamlining and Diabetes Spin-Off Benefits Offset by Lower Growth Outlook and Valuation Compression, Justifying Hold Rating
• Neutral Sentiment: Investor interest pieces and valuation checks note new GE HealthCare tie‑ups and the Altaviva launch — positive strategic context but likely already priced in and awaiting earnings results for confirmation. Medtronic (MDT) Valuation Check As New GE HealthCare Tie Up And Altaviva Launch Draw Investor Interest
• Negative Sentiment: Pre‑earnings coverage flags an expected single‑digit drop in quarterly profits — raises the risk of a downside surprise and is a chief near‑term pressure on the stock. What You Need to Know Ahead of Medtronic’s Earnings Release
• Negative Sentiment: UBS issued a pessimistic forecast for MDT’s stock price — an explicit bearish view that can amplify selling pressure, particularly with earnings imminent. UBS Group Issues Pessimistic Forecast for Medtronic (NYSE:MDT) Stock Price
• Negative Sentiment: Several investor commentaries (including Seeking Alpha) maintain a Hold view citing slow growth, high debt and competitive pressures (HUGO robotics, diabetes spin‑off uncertainties), signaling limited near‑term upside without clearer execution. Medtronic: Is This Dividend Aristocrat Finally A “Buy” Before Earnings?

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).